Heilongjiang ZBD Pharmaceutical Co., Ltd.

Shanghai Stock Exchange 603567.SS

Heilongjiang ZBD Pharmaceutical Co., Ltd. Price to Book Ratio (P/B) on January 14, 2025: 1.32

Heilongjiang ZBD Pharmaceutical Co., Ltd. Price to Book Ratio (P/B) is 1.32 on January 14, 2025, a -9.45% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Heilongjiang ZBD Pharmaceutical Co., Ltd. 52-week high Price to Book Ratio (P/B) is 1.64 on October 08, 2024, which is 24.24% above the current Price to Book Ratio (P/B).
Heilongjiang ZBD Pharmaceutical Co., Ltd. 52-week low Price to Book Ratio (P/B) is 1.17 on February 05, 2024, which is -11.56% below the current Price to Book Ratio (P/B).
Heilongjiang ZBD Pharmaceutical Co., Ltd. average Price to Book Ratio (P/B) for the last 52 weeks is 1.39.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

Shanghai Stock Exchange: 603567.SS

Heilongjiang ZBD Pharmaceutical Co., Ltd.

CEO	Mr. Jiujiang Yan
IPO Date	April 24, 2015
Location	China
Headquarters	No. 72 Hongxing Street
Employees	2,545
Sector	Health Care
Industries Pharmaceuticals Medical Instruments

Description

Heilongjiang ZBD Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of Chinese medicines in China. It offers cardiovascular and cerebrovascular, respiratory system, orthopedics, tumors, digestive system, anti-infection, mental nerve, genitourinary, and other disease fields. The company was founded in 1996 and is based in Hulin, China.

Key trends

Past 5 years